Is your GLP-1 drug causing hair loss?

Overview

A hair-loss-focused commentary discusses a newly published observational study (published July 22) examining whether GLP-1 receptor agonists—widely used for obesity and diabetes (including semaglutide and tirzepatide)—are associated with new hair loss.

What prompted the discussion

• The presenter notes that case reports and pharmacovigilance data (FAERS) have described hair loss episodes after starting GLP-1 drugs, particularly:
  • Semaglutide (e.g., Ozempic)
  • Tirzepatide (e.g., Mounjaro/Zepbound)
• Given how extremely popular and rapidly expanding GLP-1 treatments have become due to strong weight-loss effects, public interest has grown around potential side effects such as hair loss.

Study design and comparisons

• The study is described as an observational database study using University of Pennsylvania health records.
• Population:
  • Roughly 12,000 GLP-1 users
  • Compared with ~26,000 people starting other diabetes drugs:
    • SGLT2 inhibitors (e.g., Jardiance)
    • DPP-4 inhibitors
• Outcome measured:
  • Whether a new diagnosis of hair loss appeared in medical records after starting the diabetes medication.
• Key limitation emphasized:
  • Because it only captures new diagnoses, it may miss worsening of existing hair loss (i.e., people who already had hair loss before starting GLP-1s).

How confounding was handled

Unlike randomized trials, observational studies face confounding (e.g., differences in age, baseline obesity, and comorbidities). To address this, investigators used:

• Stabilized inverse probability of treatment weighting (sIPTW) to adjust for group differences.

Main findings (risk vs. absolute risk)

After adjustment, GLP-1 drugs showed a higher relative risk of hair loss compared with other diabetes drugs:

• About a 37% increase vs SGLT2 inhibitors
• About a 68% increase vs DPP-4 inhibitors

However, the presenter argues this framing can be misleading without absolute risk:

• Incidence (reported):
  • ~6.91 vs 5.04 cases per 1,000 persons per year (GLP-1 vs SGLT2)
  • ~3.85 vs 6.53 cases per 1,000 persons per year (with DPP-4 in the described comparison)
• Absolute difference summarized by the presenter:
  • An increase of only about 0.2–0.3% per year
  • Overall risk described as “extremely low” and “trivial.”

Type of hair loss observed

The presenter highlights that the study did not show increased androgenic alopecia (male/female pattern baldness) with GLP-1s.

Instead, the increased diagnoses were mainly non-scarring alopecias, consistent with telogen effluvium (including subtypes such as telogen effluvium).

For DPP-4 comparisons:

• A rare inflammatory scarring alopecia subtype (described as “scarring alopecia” such as “pseudocatricial alopecia” in the transcript) increased slightly.
• The presenter characterizes this as a remote concern, citing a very small absolute number:
  • ~0.4 additional cases per 1,000 person-years

Interpretation and conclusion

• The presenter suggests the most plausible mechanism is telogen effluvium triggered by rapid weight loss and/or nutritional stress, which is often reversible once weight stabilizes.
• Overall conclusion:
  • GLP-1-associated hair loss, if it occurs, appears rare
  • There is no evidence of worsening androgenic alopecia
• The presenter encourages viewers not to over-worry and emphasizes that risk/benefit remains favorable. If hair loss does occur, it may be temporary and potentially manageable (e.g., dose adjustment).

Presenters / contributors

• Hair Loss Witchers / the video presenter (single-person commentary; no other contributors are credited in the subtitles)